Evidence map›Paper›PMID 36406830›Full record

ArticleJournal of hematology2022

Dramatic Response After Switching MEK Inhibitors in a Patient With Refractory Mixed Histiocytosis.

Anais Roeser, Fanelie Jouenne, Laetitia Vercellino, Julien Calvani, Lauriane Goldwirt, Gwenael Lorillon, Abdellatif Tazi

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Successful treatment ofFrontiers in medicine · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Anais RoeserNational Reference Center for Histiocytoses, Pulmonology Department, AP-HP, Hopital Saint-Louis, Paris, France.
Fanelie JouenneInstitut de Recherche Saint Louis, Universite Paris Cite, INSERM U976, FR 75006, Paris France.
Laetitia VercellinoDepartment of Nuclear Medicine, AP-HP, Hopital Saint Louis, Paris, France.
Julien CalvaniInstitut de Recherche Saint Louis, Universite Paris Cite, INSERM U976, FR 75006, Paris France.
Lauriane GoldwirtDepartment of Pharmacology and Genomics, AP-HP, Hopital Saint-Louis, Paris, France.
Gwenael LorillonNational Reference Center for Histiocytoses, Pulmonology Department, AP-HP, Hopital Saint-Louis, Paris, France.
Abdellatif TaziNational Reference Center for Histiocytoses, Pulmonology Department, AP-HP, Hopital Saint-Louis, Paris, France.ORCID https://orcid.org/0000-0003-0788-7444
Assistance Publique – Hôpitaux de Paris · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the case of a patient with progressive multisystem mixed histiocytosis associating Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) involving the bone marrow, whose lesions harbored the

Indexed as

Bone marrowErdheim-Chester diseaseLangerhans cell histiocytosisPeritoneumTargeted therapy

Identifiers

PMID36406830
PMCPMC9635797
OpenAlexW4307883123

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.